





ANAH - AFES Joint Symposium 2025

14 - 16 Nov 2025 | Ariyana Convention Center, Da Nang city, Vietnam







ANAH-AFES Joint Symposium 2025

14 - 16 Nov 2025

Ariyana Convention Centre, Da Nang City, Vietnam



Meet the Professor

Ruling OUT pheochromocytoma / paraganglioma

Gregory A. Kline MD FRCPC Medical Director, UC Adrenal Research Group Clinical Professor of Medicine University of Calgary







ANAH-AFES Joint Symposium 2025

Textbook vs Reality

- Most texts/review articles teach how to diagnose ("rule-in") PPGL
- Most patients referred for query PPGL do NOT have PPGL
 - The role of the endocrinologist is usually to RULE-OUT
 - "spells" very broadly defined!
 - Hypertension (sustained)
 - Adrenal mass
 - Anxiety
 - Paroxysmal high BP









Key Points

- 1) PPGL is rare thus pre-test probability always starts LOW
- 2) Beware the reported reference interval
- 3) Inpatient metanephrines are highly unreliable on their own
- 4) PPGL are rarely anatomically occult
- 5) Adrenal pheo lesions are not low density
- 6) Supine age-adjusted plasma nor/metanephrine as the best test
- 7) A way forward based on PRE-TEST PROBABILITY







Pre-Test Probability

LOW	MODERATE - HIGH
Primary goal:	Primary goal:
RULE OUT	RULE IN
(confirm absence)	(confirm presence)








ANAH-AFES Joint Symposium 2025


Da Nang City, Vietnam

1) PPGL is rare but often considered

- Incidence 0.66 per 100,000 people per year*
- 0.32 cases of pheo per 100,000 people per year
- In adults only,
- 3.27 and 3.84 pheo per 100,000 adults per year (M/F)
- Ages 60-79,
- 8.8 and 14.7 pheo per 100,000 older adults per year (M/F)



All PPGL Men-blue Women - red




20-39 40-59

Age, years

children adults

(≥20)



60-79

European Journal of Endocrinology (2020) **184**, 19–28







ANAH-AFES Joint Symposium 2025

Ariyana Convention Centre, Da Nang City, Vietnam

Biochemistry

Overall prevalence of 0.57% among those who were tested

European Journal of Endocrinology (2020) 184, 19-28







ANAH-AFES Joint Symposium 2025

4 - 16 Nov 2025 Ariyana Con

PPGL is RARE

- Pre-test probability will be LOW unless:
- * prior PPGL in the patient or family
- * known genetic syndrome
- * higher density/atypical adrenal lesion
- * very high metanephrines
- As you decide next steps, let your pre-test probability GUIDE YOU








ANAH-AFES Joint Symposium 2025

- 16 Nov 2025 Arryana

2) Know your reference intervals



Among a population where case-finding using Urine metanephrines takes place:

- a. Positivity rate: 20.2%
- b. Given expected prevalance, most abnormals in 13,000 tests will be FP
- a. The importance of the derivation population

Dashed horizontal line = age-dependent lab ULN

Clinical Biochemistry 77 (2020) 26-31








ANAH-AFES Joint Symposium 2025

14 - 16 Nov 2025


3) What about inpatients?

- Urine MN/NM database April 2012 June 2018
- PPGL epi database, same time frame
- Inpatient measures = 1102 (wards 842, ICU 132)

Population distribution of UNM in inpatients vs outpatients vs PPGL



Population distribution of UMN in inpatients vs outpatients vs PPGL









Breaking Boundaries in Adrenal Disorders

ANAH-AFES Joint Symposium 2025

Ariyana Convention Centre Da Nang City, Vietnam

Any elevation in either NM or MN or both:

Outpt: 18.7%

Hospital ward: 34.4%

Critical care: 67.4%

Large overlap between PPGL and inpts

Kline GA et al. Am J Med 2021 Aug 1;134(8):1039-46.







ANAH-AFES Joint Symposium 2025

- 16 Nov 2025 Ariyana Conventi

When does PPGL become a likely diagnosis?

location	analyte	98% spec, Umol/d	PPV with Prev 0.7%
Outpt	NM	> 4.35	17%
	MN	> 1.35	15%
Ward	NM	> 6.95	14%
	MN	> 1.95	14%
ICU/CCU	NM	> 14.25	10%
	MN	> 3.30	11%

Kline GA et al. Am J Med 2021 Aug 1;134(8):1039-46.







ANAH-AFES Joint Symposium 2025

Ariyana Convention Centre Da Nang City, Vietnam

4) Imaging: pheo lesions are not occult

CANADA (2013-2018)

- N=239
- Adrenal location = 49%
- Abdominal location = 12%
- Thoracic = 1%
- H&N = 37%
- Size (median, IQR) = 3.2 cm [2.0-5.0]

DENMARK (1977-2015)

- N=567
- Adrenal location = 86%
- Size (median, range) = 4.0 cm (1.1-23.0)

European Journal of Endocrinology (2020) **184**, 19–28







ANAH-AFES Joint Symposium 2025

Imaging

USA (1980-2018)

- N=390
- Adrenal location = 100% (by design)
- Size (median, range) = 5.1 cm [1.0-28.0]

SPAIN (1980-2016)

- N=106
- Adrenal location = 86%
- Size (median, IQR) = 4.3 cm (3.0-6.0)

Iglesias P, Revista Clínica Española 2021 Jan 1;221(1):18-25.

Am J Surg Pathol • Volume 45, Number 9, September 2021







ANAH-AFES Joint Symposium 2025

Ariyana Convention Centre Da Nang City, Vietnam

Imaging

PHILLIPINES (2010-2021)

- N=30
- Adrenal location = 100%
- Size (mean) = 7.0 cm
- 83% > 4 cm

UK (1977-2015)

- N=167
- Adrenal location = 86%
- Size (median, range) = 4.5 cm (1.0-21.0)

Hernandez E, Journal of the ASEAN Federation of Endocrine Societies. 2024 Sep 9;39(2):41.

Aggarwal S, J Clin Endocrinol Metab 2024 Jan; 109(1):e389-96.







ANAH-AFES Joint Symposium 2025

14 - 16 Nov 2025 Ariy

5) Density of Lesions: pheos are not adenomas

- multi-centre retrospective, n=376 confirmed PPGL
 - 99.5% had unenhanced CT HU > 10
 - Washout data unreliable
- N= 46 PCC vs 98 adrenal adenomas
 - 100% of PCC had unenhanced CT HU > 10
 - Washout criteria not specific for PCC







ANAH-AFES Joint Symposium 2025

ANAH-AFES Joint Symposium 2025

Anale New 2025 | Ariyana Convention Centre.

APPLICATION: this is **NOT** like PA or Cushings

- 1. Truly "occult" PPGL is exceedingly rare within a very rare disease
- 2. PPGL lesions are BIG
- 3. PPGL lesions are DENSE
 - 1. If you are puzzled by the biochemistry this is one time when imaging could be done instead of sorting out the labs.
 - 2. Absence of an obvious lesion in CT chest/abd/pelvis markedly decreases post-test probability
 - 3. If a lesion is found but is < 10 HU (adrenal) highly unlikely to be PCC
 - 4. If a lesion is found and is > 10 HU, you shift from RULING OUT to RULING IN







Breaking Boundaries in Adrenal Disorders


ANAH-AFES Joint Symposium 2025

- 16 Nov 2025 Ariyana Convention Cen Da Nang City, Vietnam

6) Plasma metanephrines

- Plasma normetanephrine is strongly influenced by upright posture
- Seated plasma normetanephrine is highly age-dependent
- Use of a plasma normetanephrine reference interval that is not posture or age-adjusted can have just as many false positives as urine normetanephrine











Low Pre-test probability: RULE OUT

- Consider the reference interval upper limit
- 2. Most PPGL have results > 2-3 x URL,
- 3. Inpatients can have results > 5 X URL
- 4. If you have access: supine, age-adjusted plasma normetanephrine
- Easiest way forward may be imaging: if you don't see an obvious, higher density lesion and pre-test probability was low, STOP. The patient almost certainly does not have PPGL.
- 6. Consider the differential diagnosis and redirect or follow periodically

HIGH Pre-test probability: RULE IN

- Family history/genetics, prior PPGL, very high biochemical screen, high-density lesion on imaging
- 2. Not much more needed! Advanced imaging...?
- 3. Surgery likely warranted; it's OK to be wrong if pre-test probability was high and atypical lesion present







ANAH-AFES Joint Symposium 2025

- 45 year old nurse with 8 month history of episodic high BP, several emergency room visits for high BP
- No target organ damage, BP can be up to 180/110
- No family history of PPGL-like disease
- Pre-test probability: LOW
- 24 hour urine normetanephrine 3.9 nmol/d (< 3.0 umol/d)
- 24 hour urine metanephrine 0.3 umol/d (< 0.9 umol/d)
- Ideal screening population reference interval URL < 4.3 umol/d
 - NORMAL
 - STOP







ANAH-AFES Joint Symposium 2025

- 79 year old man admitted to neurosurgical ICU with intra-cerebral hemorrhage
- BP highly variable, often very high
- Day 4 abdominal distention, CT abdomen
- Incidental 2.2 cm low density (-12 HU) left adrenal mass
- 24 hour urine normetanephrine 9.9 umol/d (< 4.3 umol/d)
- 24 hour urine metanephrine 1.4 umol/d (<1.3 umol/d)
- Pre-test probability: LOW
- Decision: STOP (maybe later ---? PA)







ANAH-AFES Joint Symposium 2025

- 47 year old woman with chronic depression/anxiety and "spells"
- Using SNRI (venlafaxine), cannot be stopped.
- No family history of PPGL
- 24 hour urine normetanephrine 4.8 umol/d (< 3.9) repeatedly
- Historically clonidine suppression test?
- Supine plasma normetanephrine with age-adjusted interpretive range not available
- Pre-test probability: LOW
- CT chest/abd/pelvis no lesions seen = STOP







ANAH-AFES Joint Symposium 2025

- 25 year old man with incidental adrenal lesion found after motorcycle crash
- CT 4.5 cm heterogeneous adrenal lesion, 37 HU unenhanced
- Mild hypertension but no other symptoms
- Outpatient 24 hour urine normetanephrine 7.9 umol/d, metanephrine 3.4 umol/d
- Pre-test probability: HIGH
- Decision surgery





ANAH-AFES Joint Symposium 2025

Breaking Boundaries in Adrenal Disorders

What else could it be?

- Anxiety/PTSD
- Food, wine, drugs, procedures
- Chest pain, abdominal pain, constipation, cardiomyopathy, MSOF
- Baro-reflex injury, POTS, OSA, carcinoid syndrome, LMS, autonomic neuropathy, RAS, hyperventilation, pseudopheochromocytoma, arteriosclerotic hemodynamics, acute intermittent porphyria etc.







ANAH-AFES Joint Symposium 2025

4 - 16 Nov 2025 Ariyana Convention C

Thank you!

gakline@ucalgary.ca